Latest Articles

Researchers at the University of Cambridge and DIOSynVax have reported early human trial results for an AI-designed pan-sarbecovirus vaccine candidate. The study is still early, but it gives AI biotech investors a clearer proof point to watch as the field moves from discovery tools toward clinical products.